All In Biotech

Drug Trial Radar · NCT05007782

Study of Denikitug (GS-1811) Given Alone or With Zimberelimab in Adults With Advanced Solid Tumors

A Phase 1 Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Denikitug (GS-1811), an Afucosylated Anti-CCR8 Monoclonal Antibody, as Monotherapy and in Combination With an Anti-PD-1 Monoclonal Antibody in Adults With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

304

Actual

Start

Aug 18, 2021

Primary completion

Dec 2028

Study completion Dec 2028

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first-in-human (FIH) study to evaluate the safety and tolerability and to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of denikitug (also known as GS-1811) as monotherapy and in combination with zimberelimab in participants with advanced solid tumors. This study will be conducted in 6 parts (Parts A, B, and E: monotherapy, Parts C and D: combination therapy, and Part F for both monotherapy and combination therapy) in participants with advanced solid tumors who have received, been intolerant to, or been ineligible for all treatments known to confer clinical benefit or in participants with select solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

  • DenikitugDrug

    Administered Intravenously

  • ZimberelimabDrug

    Administered Intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Dose Limiting Toxicities (DLTs) in Part A and CTime frame: Day 1 Through Day 21
  2. Percentage of Participants Experiencing Adverse Events (AEs) According to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0Time frame: First dose to End of Treatment (up to 12 months for monotherapy and 24 months for combination therapy) plus 90 days
  3. Percentage of Participants Experiencing Laboratory Abnormalities According to the NCI CTCAE v5.0Time frame: First dose to End of Treatment (up to 12 months for monotherapy and 24 months for combination therapy) plus 90 days

Locations

25 sites in 5 countries. Site status is shown where the registry gives one.

  • University of California San Diego

    La Jolla, California

  • Stanford Cancer Center

    Palo Alto, California

  • Smilow Cancer Center

    New Haven, Connecticut

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Tennessee Oncology, PLLC

    Nashville, Tennessee

  • University of Texas Southwestern Medical Center

    Dallas, Texas

  • Sarah Cannon Research Institute at Mary Crowley

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • NEXT Oncology

    San Antonio, Texas

  • University of Wisconsin Clinical Sciences Center

    Madison, Wisconsin

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Monash Medical Centre

    Clayton, Victoria, Australia

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia

  • University Health Network, Princess Margaret Cancer Centre

    Toronto, Canada

  • Hospital Universitari Vall d´Hebrón

    Barcelona, Spain

  • MD Anderson Cancer Center

    Madrid, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, Spain

  • Hospital Universitario Quironsalud Madrid

    Madrid, Spain

  • Clinica Universidad de Navarra

    Pamplona, Spain

  • Changhua Christian Hospital

    Changhua, Taiwan

  • Chi Mei Hospital, Liouying

    Tainan, Taiwan

  • National Taiwan University Cancer Center (NTUCC)

    Taipei, Taiwan

  • National Taiwan University Hospital

    Taipei, Taiwan

  • Taipei Veterans General Hospital

    Taipei, Taiwan

  • Chang Gung Medical Foundation Linkou Chang Gung Memorial Hospital

    Taoyuan City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.